Delivery Order SPE2DB20D1100-SPE2DB25FE1QT
- Not listed
- The Defense Logistics Agency (DLA) awarded a $12,019.28 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. The contract was competitively awarded without set-aside provisions and carries an ultimate completion date of September 18, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency has awarded a delivery order valued at $360,578.40 to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 ml vials. This is a firm fixed-price delivery order with an ultimate completion date of October 21, 2025, issued under a competitive procurement with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,019.28 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. This firm fixed price contract, awarded on July 23, 2025, with an ultimate completion date of August 13, 2025, represents a competitively awarded, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- The Defense Logistics Agency has awarded a delivery order valued at $120,192.80 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of May 15, 2025. The awardee, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $48,077.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on September 19, 2025, with an ultimate completion date of October 10, 2025. This non-competitive delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $24,038.58 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed price delivery order with an ultimate completion date of June 24, 2025, and represents a non-competitive, non-set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $48,077.16. The contract is firm fixed price with no set-aside designation, indicating competitive award, and is scheduled for completion by August 28, 2025. AmerisourceBergen will perform the work from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $96,154.24 to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 24, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. Ocrevus is a monoclonal antibody therapeutic used to treat multiple sclerosis,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $120,192.80 and a firm fixed price structure. The order is scheduled for completion by October 14, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This non-competitive delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $48,077.16 firm fixed price delivery order to AmerisourceBergen Drug Corp for 10 milliliter vials of Ocrevus 300 mg on September 10, 2025, with an ultimate completion date of October 1, 2025. This contract was not set-aside and represents a competitive award to the pharmaceutical distributor. Performance will occur at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child delivery order, this award falls under AmerisourceBergen's...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1QTDelivery Order
The Defense Logistics Agency (DLA) awarded a $600,964 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials, a pharmaceutical product used in the treatment of multiple sclerosis. The contract, awarded on September 29, 2025, with an ultimate completion date of October 21, 2025, represents a competitive procurement with no set-aside designation. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies an extensive portfolio of medications and medical supplies to support military and veteran healthcare systems. The company's contract history demonstrates consistent capability in fulfilling federal procurement requirements through open competition, with delivery orders utilizing firm fixed pricing across a wide range of therapeutic domains. This particular delivery order for Ocrevus supports the broader DLA Troop Support Medical mission to ensure consistent pharmaceutical supply chains for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $601.0k | 9/29/25 |